Analysis of the impact of timing for Zejula maintenance treatment in newly diagnosed advanced ovarian cancer is presented at the 2022 International Gynecologic Cancer Society Meeting
Zai Lab Limited will present a poster featuring initiation timing analysis from the Phase III PRIME study of Zejuka (niraparib) as maintenance therapy at the upcoming 2022 International Gynecologic Cancer Society (ICGS) Annual Meeting
This post-hoc analysis of the PRIME Phase III study evaluated adults with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based chemotherapy, and they were randomized to receive niraparib maintenance treatment or placebo within 12 weeks after chemotherapy completion.
The results are as follows: i. For patients who received niraparib treatment less than 9 weeks after chemotherapy completion, the median progression-free survival (PFS) (95% CI) was measured at 29.4 months with niraparib versus 8.3 months with placebo (HR =0.31; 95% CI, 0.20–0.48). ii. For patients who received niraparib at 9 – 12 weeks after chemotherapy completion, the median PFS was 24.7 months with niraparib versus 10.8 months with placebo (HR=0.60; 95% CI, 0.41–0.89). iii. The initiation timing of niraparib maintenance treatment had no significant impact on its safety profile.This subgroup analysis provides evidence to support the initiation of niraparib maintenance treatment in patients with newly diagnosed advanced ovarian cancer within 12 weeks after chemotherapy completion.
Related news and insights
In a 14 to 2 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted that the benefit-risk profile of melphalan flufenamide (Pepaxto) is not favorable for the approved indicated population of patients with relapsed/refractory multiple myeloma
In an 8 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted that the final overall survival (OS) data submitted did not demonstrate a strong enough benefit-risk ratio to support the continued approval of duvelisib (Copiktra) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least 2 prior therapies